Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
株式のランク #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
株価
$50.95
時価総額
$226.41B
変化(1日)
2.58%
変化(1年)
-26.16%
DK
取引 Novo Nordisk A/S (NVO)

カテゴリー

Novo Nordisk A/S(NVO)の利益
Mar 2026 時点の利益 TTM: $24.72B
Novo Nordisk A/S の最新の財務報告によると、同社の現在の利益は $24.72B です。2024 年には $17.75B の利益を上げ、これは 2023 年の利益 $15.50B と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Novo Nordisk A/S の利益の推移(2000 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $24.72B 25.36%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
同業他社の利益
企業 利益 利益の差
$5.17B -79.10%
US
$5.16B -79.14%
US
$2.14B -91.35%
BE
$1.48B -94.01%
NL
$586.40M -97.63%
US